PT1106178E - Utilizacao de ibudilast para a preparacao de um medicamento para o tratamento da esclerose multipla - Google Patents

Utilizacao de ibudilast para a preparacao de um medicamento para o tratamento da esclerose multipla

Info

Publication number
PT1106178E
PT1106178E PT98936715T PT98936715T PT1106178E PT 1106178 E PT1106178 E PT 1106178E PT 98936715 T PT98936715 T PT 98936715T PT 98936715 T PT98936715 T PT 98936715T PT 1106178 E PT1106178 E PT 1106178E
Authority
PT
Portugal
Prior art keywords
ibudilast
multiple sclerosis
treatment
medication
usefulness
Prior art date
Application number
PT98936715T
Other languages
English (en)
Inventor
Sakoda Saburo
Original Assignee
Sakoda Saburo
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sakoda Saburo, Kyorin Seiyaku Kk filed Critical Sakoda Saburo
Publication of PT1106178E publication Critical patent/PT1106178E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicinal Preparation (AREA)
PT98936715T 1998-08-10 1998-08-10 Utilizacao de ibudilast para a preparacao de um medicamento para o tratamento da esclerose multipla PT1106178E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1998/003548 WO2000009127A1 (fr) 1998-08-10 1998-08-10 Traitements contre la sclerose en plaques

Publications (1)

Publication Number Publication Date
PT1106178E true PT1106178E (pt) 2005-02-28

Family

ID=14208769

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98936715T PT1106178E (pt) 1998-08-10 1998-08-10 Utilizacao de ibudilast para a preparacao de um medicamento para o tratamento da esclerose multipla

Country Status (11)

Country Link
US (1) US6395747B1 (pt)
EP (1) EP1106178B1 (pt)
JP (1) JP4828003B2 (pt)
AT (1) ATE283047T1 (pt)
AU (1) AU8562198A (pt)
CA (1) CA2339934C (pt)
DE (1) DE69827853T2 (pt)
DK (1) DK1106178T3 (pt)
ES (1) ES2231998T3 (pt)
PT (1) PT1106178E (pt)
WO (1) WO2000009127A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302588A1 (en) * 2002-12-03 2004-06-23 Kyorin Pharmaceutical Co., Ltd. Phosphodiesterase 10a inhibitors
NZ547389A (en) * 2003-11-21 2009-11-27 Combinatorx Inc Combinations of a compound such as ibudilast and a corticosteroid for the treatment of inflammatory disorders
US20060093578A1 (en) * 2004-11-04 2006-05-04 Kyorin Pharmaceutical Co., Ltd. Method and composition for treating multiple sclerosis
US7534806B2 (en) * 2004-12-06 2009-05-19 Avigen, Inc. Method for treating neuropathic pain and associated syndromes
KR100780479B1 (ko) 2006-05-08 2007-11-28 윈셋파마 주식회사 이부딜라스트 함유 경구용 제제 및 이의 제조방법
EP2026804A1 (en) * 2006-05-31 2009-02-25 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
ES2392116T3 (es) * 2007-01-30 2012-12-04 Avigen, Inc. Procedimientos para el tratamiento del dolor agudo y subcrónico
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
CA2970273C (en) * 2007-07-11 2020-04-14 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
WO2018119262A1 (en) 2016-12-22 2018-06-28 Medicinova, Inc. Methods of treating glioblastoma multiforme using ibudilast
JP2021512921A (ja) 2018-02-12 2021-05-20 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン
US20190247369A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients
WO2019193091A1 (en) * 2018-04-05 2019-10-10 Universiteit Hasselt Selective pde4d inhibitors against demyelinating diseases
US10946071B2 (en) 2018-10-09 2021-03-16 Medicinova, Inc. Combination of ibudilast and interferon-beta and methods of using same
WO2020081941A1 (en) 2018-10-19 2020-04-23 Medicinova, Inc. Methods of treating ophthalmic disease/disorder or injury with ibudilast
WO2020251748A1 (en) * 2019-06-11 2020-12-17 Yale University Novel treatment for wolfram syndrome
WO2021061554A1 (en) 2019-09-23 2021-04-01 Medicinova, Inc. Ibudilast oral formulations and methods of using same
CN115335049A (zh) 2020-04-06 2022-11-11 美迪诺亚公司 降低患者中巨噬细胞迁移抑制因子的血浆水平的方法
WO2022164948A1 (en) 2021-01-29 2022-08-04 Medicinova, Inc. Methods of treating chemical gas exposure
CN117940128A (zh) 2021-07-26 2024-04-26 美迪诺亚公司 异丁司特用于防止眼癌转移
CA3231869A1 (en) 2021-09-21 2023-03-30 Medicinova, Inc. Ibudilast in combination therapy for use in the treatment of glioblastoma
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
US20230285367A1 (en) 2022-02-01 2023-09-14 Medicinova, Inc. Methods of treating post-covid condition(s)
US20240016729A1 (en) 2022-07-13 2024-01-18 Medicinova, Inc. Injectable formulations of ibudilast

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
CA2197984A1 (en) * 1994-08-29 1996-03-07 Kazuhisa Takayama Novel naphthyridine derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
ES2231998T3 (es) 2005-05-16
EP1106178B1 (en) 2004-11-24
DK1106178T3 (da) 2005-02-28
CA2339934C (en) 2008-06-03
EP1106178A4 (en) 2001-11-21
DE69827853T2 (de) 2005-12-08
JP4828003B2 (ja) 2011-11-30
EP1106178A1 (en) 2001-06-13
US6395747B1 (en) 2002-05-28
DE69827853D1 (de) 2004-12-30
ATE283047T1 (de) 2004-12-15
CA2339934A1 (en) 2000-02-24
WO2000009127A1 (fr) 2000-02-24
AU8562198A (en) 2000-03-06

Similar Documents

Publication Publication Date Title
PT1106178E (pt) Utilizacao de ibudilast para a preparacao de um medicamento para o tratamento da esclerose multipla
ES2107459T3 (es) Mejora de la regulacion represora de enfermedades autoinmunes por administracion oral o enteral de autoantigenos.
ATE76747T1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
BR9908488A (pt) Composição farmacêutica de topiramato
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
BR9909192A (pt) Preparações galênicas de meloxicam para administração oral
PT1002792E (pt) Compostos de 2-aminopropano-1,3-diol, sua utilizacao medicinal e intermediariosda sintese dos mesmos
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
ATE85976T1 (de) Pharmakologisch aktive derivate von tryptophan und diese enthaltende pharmazeutische zusammensetzungen.
ES2145818T3 (es) Utilizacion de la (s)-(-)-alfa-etil-2-oxo-1-pirrolidin-acetamida para la preparacion de medicamentos destinados al tratamiento de la ansiedad.
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
ATE87484T1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
NO302523B1 (no) Heterosykliske forbindelser, farmasöytiske preparater som omfatter dem, og anvendelse av forbindelsene for fremstilling av medikamenter
ES2051834T3 (es) El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad.
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
CA2171675A1 (fr) Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
KR920002151A (ko) 15-케토-프로스타글란딘 화합물에 의한 염증성 질환 치료
TNSN99080A1 (fr) Composes azapolycycliques condenses a noyau aryle, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2358406A1 (fr) Derives d'acides 5-aroyl-1,2-dihydro-3h-pyrrolo (1,2-a)pyrrole-1-carboxyliques, leur obtention et leur application a titre de medicament
ES2068216T3 (es) Compuestos de tienotriazolodiazepina y usos farmaceuticos de los mismos.
SE8500996D0 (sv) Method of treatment
ATE85334T1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
KR910011807A (ko) 4-벤질-5-페닐-2,4-디히드로-3h-1,2,4-트리아졸-3-온 및 진경제로서의 그 의 용도
RU94002476A (ru) Лекарственное средство
FR2392990A1 (fr) Medicament a base d'un compose heterocyclique bicyclique condense